Title
Category
Credits
Event date
Cost
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
Pulmonary arterial hypertension (PAH) is a complex and heterogenous disease, which remains challenging to diagnose and treat. During this webinar series, you will have a chance to hear from leading PAH experts about the screening, diagnosis, and treatment of PAH, as well as recent advances in the treatment landscape and their interpretation to patient care.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
Pulmonary arterial hypertension (PAH) is a complex and heterogenous disease, which remains challenging to diagnose and treat. During this webinar series, you will have a chance to hear from leading PAH experts about the screening, diagnosis, and treatment of PAH, as well as recent advances in the treatment landscape and their interpretation to patient care.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
During this activity, experts will discuss the rationale and clinical trial data for the use of non-steroidal mineralocorticoid receptor antagonists (MRAs) in patients with diabetic kidney disease (DKD), as well as the interpretation of these data and their potential application to patient care.This activity is also part of the DKD Digital Highlights Hub.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
Diabetic kidney disease (DKD) remains one of the major causes of morbidity and mortality in patients with type 2 diabetes. Despite optimized glycemic control and renin-angiotensin-aldosterone system (RAAS) inhibitor therapy, many patients with DKD progress to kidney failure. Recent advances in the understanding of disease pathophysiology have opened up new avenues of treatment, including targeting mineralocorticoid receptor overactivation with novel, non-steroidal mineralocorticoid receptor antagonists (MRAs).
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
Patients with diabetes and PAD, particularly those with concomitant polyvascular disease, are at a greater risk for future adverse cardiovascular and limb events.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
Chronic obstructive pulmonary disease (COPD) is a chronic, complex disease with multiple systemic effects, including cardiometabolic conditions, which not only influence patient adherence by adding to the burden of pharmacotherapy, but may also impact COPD therapeutic decisions.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
This clinical brief, adapted from a presentation at the 2021 CMHC Spring meeting, offers a concise overview of recent trials and developments in antithrombotic and antiplatelet therapy in high-risk cardiometabolic patients with coronary artery disease (CAD) or peripheral artery disease (PAD). 
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
Several cardiometabolic comorbidities, including overweight/obesity, dyslipidemia, cardiovascular diseases, hypertension, and type 2 diabetes or insulin resistance, are common in patients with narcolepsy.  Often these disorders are overlooked, but they have important implications in the management of  these patients.  Some medications used to treat symptoms of narcolepsy may have potential negative effects on cardiovascular health, including in patients that are sensitive to sodium, such as those with hypertension, heart failure, or impaired renal function.  However, long-term data on the c
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
This clinical brief, adapted from a presentation at the 2021 CMHC Spring meeting, offers an overview of insulin pumps and insulin delivery systems for T2DM, as well as expert feedback and practical strategies on how to integrate them to patient care.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
The rapid rise of cardiometabolic disease and risk factors in children and adolescents is a huge cause of concern now and in the future. According to the CDC, close to 14 million children and adolescents aged 2-19 years have obesity in the US, with the prevalence increasing by more than 33% in the last two decades. In turn, this increase in obesity is strongly associated with increased rates of hypertension, dyslipidemia, type 2 diabetes, as well as increased overall cardiovascular risk in the pediatric population.

Pages